[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100416561":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":31,"locations":38,"responsibleParty":62,"collaborators":30,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":30,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":30,"overallStatus":41,"whyStopped":30,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Yale University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Delta-9-Tetrahydrocannabinol (THC)","ACTIVE_COMPARATOR","4 mg vaporized THC will be administered.",[13],"Drug: Inhaled THC",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Inhaled placebo (no active cannabinoids)",[19],"Drug: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Inhaled THC","4 mg inhaled THC",[9],[27],"Delta-9-Tetrahydrocannabinol",{"type":22,"name":15,"description":17,"armGroupLabels":29,"otherNames":30},[15],null,[32],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Carly Hewes, BS","CONTACT","2039325711","7411","carly.hewes@yale.edu",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine","RECRUITING","West Haven","Connecticut","06516","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-72.94705,41.27065,{"lat":51,"lon":50},[54,59],{"name":55,"role":34,"phone":56,"phoneExt":57,"email":58},"Christina Luddy, BS","203-932-5711","4549","christina.luddy@yale.edu",{"name":60,"role":61,"phone":30,"phoneExt":30,"email":30},"Mohini Ranganathan, MD","PRINCIPAL_INVESTIGATOR",{"type":61,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Mohini Ranganathan","Associate Professor of Psychiatry","100416561","phase-1-gender-related-differences-in-the-acute-effects-of-delta-9-tetrahydrocannabinol-in-healthy-humans-sub-study-ii-100416561",false,"NCT04704271","Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II","THC-Gender-II","Inclusion Criteria:\n\n* At least one lifetime exposure to cannabis\n* Good physical and mental health\n\nExclusion Criteria:\n\n* Cannabis naïve individuals\n* Major current or recent stressors",true,"ALL","18 Years","55 Years",{"count":77,"type":78},100,"ESTIMATED","INTERVENTIONAL",[81],"PHASE1","The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.",[84],"Cannabis","2026-04-23",{"date":87,"type":88},"2026-04-29","ACTUAL",{"date":90,"type":88},"2019-10-09",{"date":92,"type":78},"2027-12-01",{"name":5,"class":6},1]